<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02009982</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00062061</org_study_id>
    <nct_id>NCT02009982</nct_id>
  </id_info>
  <brief_title>Cardioneuroablation for Neurocardiogenic Syncope</brief_title>
  <acronym>Ablate-NCS</acronym>
  <official_title>Cardioneuroablation for Neurocardiogenic Syncope</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David B. De Lurgio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biosense Webster, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness of cardioneuroablation for the
      treatment of neurocardiogenic syncope (NCS), also known as &quot;vaso-vagal&quot; syncope. Syncope is a
      general term for passing out spells and neurocardiogenic syncope is a specific form of
      passing out spells caused by sudden drops in heart rate or blood pressure. Although the
      specific mechanisms of NCS are not well understood, it is believed that some people are prone
      to developing passing out spells in specific situations such as standing up for a long period
      of time, pain or nausea. In these situations, the body reacts with a paradoxical reflex which
      leads to a drop in blood pressure and heart rate and causes passing out. Certain types of
      medications are used to treat NCS including beta-blockers, midodrine and florinef, among
      others. However, none of these medications are particularly effective at preventing passing
      out spells and many people continue to have episodes despite trying different medications.

      Cardioneuroablation is a new form of treatment for NCS. The term ablation means using a wire
      to make small electrical burns in the heart. Ablation has been used for many years to treat
      other electrical disturbances in the heart but the use of ablation to treat NCS is a new
      application. The goal of cardioneuroablation is to identify areas within the heart which are
      believed to initiate the reflex which triggers the drop in heart rate and blood pressure that
      leads to passing out. In preliminary studies, it has been suggested that cardioneuroablation
      may be significantly more effective than medications at preventing passing out spells for
      people with NCS.

      Hypothesis: Cardioneuroablation of vagal inputs in the left atrium may serve as an effective
      treatment modality for the prevention of NCS by blunting the initial trigger of the cascade
      that leads to symptoms and syncope.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Syncope Recurrence Rate</measure>
    <time_frame>12 Months</time_frame>
    <description>The primary endpoint for the study is recurrence of syncope within the 12 month follow-up protocol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Serious Adverse Events</measure>
    <time_frame>12 Months</time_frame>
    <description>The secondary endpoint for this study will be the incidence of serious adverse events related to the study procedure within the 12 month follow-up protocol</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Neurocardiogenic Syncope</condition>
  <condition>Vasovagal Syncope</condition>
  <arm_group>
    <arm_group_label>Cardioneuroablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will receive the cardioneuroablation procedure using the Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Medical Thearpy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in this group will not receive the cardioneuroablation and will continue to be managed using standard medical therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cardioneuroablation</intervention_name>
    <description>Catheter Ablation of Vagal Inputs in Left Atrium</description>
    <arm_group_label>Cardioneuroablation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter</intervention_name>
    <description>This is the device that will be used to perform the Cardioneuroablation procedure</description>
    <arm_group_label>Cardioneuroablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is able and willing to sign and date the Patient Consent Form

          -  Subject is 18 years of age or older

          -  Subject is expected to remain available for the follow-up protocol

          -  Subject is willing to comply with the follow-up procedures

          -  Subject has medically documented history of neurocardiogenic syncope

          -  Subject has had 3 episodes of syncope or presyncope in last 12 months

          -  Subject has had a positive tilt table test, defined as the presence of syncope or
             presyncope associated with abrupt hypotension (SBP &lt; 70 mmHg) or bradycardia (HR &lt; 40
             bpm), with or without sublingual nitroglycerin provocation or atropine challenge

          -  Subject has been tried on at least one pharmacologic therapy for at least 4 weeks

        Exclusion Criteria:

          -  Subject has signs and symptoms of an active infection (i.e. fever, elevated white
             blood cell count, etc.) which has not been treated and/or has not demonstrated
             improvement in white blood cell count and resolution of fever

          -  Subject is pregnant or planning to become pregnant within the study protocol follow-up

          -  Subject is enrolled or planning to participate in a concurrent drug and/or device
             study during the course of this study that would confound study results as determined
             by the study physician

          -  Subject is unwillingly to comply with the randomization procedure

          -  Subject has had no syncopal episodes in last six months while on medical therapy

          -  Subject has one of the following conditions that is the documented source of syncope:
             sick sinus syndrome, sinus node or atrioventricular conduction deficiencies,
             ventricular tachyarrhythmias, pulmonary hypertension, hypertrophic cardiomyopathy,
             history of transient ischemic attack, seizure disorders, subclavian steal syndrome, or
             drug-induced syncope

          -  Subjects with a myocardial infarction within last six months

          -  Subjects with severe heart failure (NYHA class III or IV), previous heart surgery,
             structural heart disease, or an infiltrative cardiac disease

          -  Subject is contraindicated for left-atrial ablation, as determined by enrolling
             physician
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David B DeLurgio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2013</study_first_submitted>
  <study_first_submitted_qc>December 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2013</study_first_posted>
  <results_first_submitted>September 16, 2016</results_first_submitted>
  <results_first_submitted_qc>September 16, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 4, 2016</results_first_posted>
  <last_update_submitted>September 16, 2016</last_update_submitted>
  <last_update_submitted_qc>September 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>David B. De Lurgio</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Fainting</keyword>
  <keyword>Ablation</keyword>
  <keyword>Cardiology</keyword>
  <keyword>Cardiac Electrophysiology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syncope</mesh_term>
    <mesh_term>Syncope, Vasovagal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No due to limited data set and study ending.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cardioneuroablation</title>
          <description>Patients in this group received the cardioneuroablation procedure using the Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter
Cardioneuroablation: Catheter Ablation of Vagal Inputs in Left Atrium
Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter: This is the device that was used to perform the Cardioneuroablation procedure</description>
        </group>
        <group group_id="P2">
          <title>Standard Medical Thearpy</title>
          <description>Patients in this group did not receive the cardioneuroablation and were managed using standard medical therapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cardioneuroablation</title>
          <description>Patients in this group received the cardioneuroablation procedure using the Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter
Cardioneuroablation: Catheter Ablation of Vagal Inputs in Left Atrium
Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter: This is the device that was used to perform the Cardioneuroablation procedure</description>
        </group>
        <group group_id="B2">
          <title>Standard Medical Thearpy</title>
          <description>Patients in this group did not receive the cardioneuroablation and were managed using standard medical therapy.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Syncope Recurrence Rate</title>
        <description>The primary endpoint for the study is recurrence of syncope within the 12 month follow-up protocol</description>
        <time_frame>12 Months</time_frame>
        <population>No data was analyzed due to low enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>Cardioneuroablation</title>
            <description>Patients in this group received the cardioneuroablation procedure using the Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter
Cardioneuroablation: Catheter Ablation of Vagal Inputs in Left Atrium
Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter: This is the device that was used to perform the Cardioneuroablation procedure</description>
          </group>
          <group group_id="O2">
            <title>Standard Medical Thearpy</title>
            <description>Patients in this group did not receive the cardioneuroablation and were managed using standard medical therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Syncope Recurrence Rate</title>
          <description>The primary endpoint for the study is recurrence of syncope within the 12 month follow-up protocol</description>
          <population>No data was analyzed due to low enrollment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Serious Adverse Events</title>
        <description>The secondary endpoint for this study will be the incidence of serious adverse events related to the study procedure within the 12 month follow-up protocol</description>
        <time_frame>12 Months</time_frame>
        <population>No data was analyzed due to low enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>Cardioneuroablation</title>
            <description>Patients in this group received the cardioneuroablation procedure using the Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter
Cardioneuroablation: Catheter Ablation of Vagal Inputs in Left Atrium
Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter: This is the device that was used to perform the Cardioneuroablation procedure</description>
          </group>
          <group group_id="O2">
            <title>Standard Medical Thearpy</title>
            <description>Patients in this group did not receive the cardioneuroablation and were managed using standard medical therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Serious Adverse Events</title>
          <description>The secondary endpoint for this study will be the incidence of serious adverse events related to the study procedure within the 12 month follow-up protocol</description>
          <population>No data was analyzed due to low enrollment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Data for adverse events were collected for 12 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cardioneuroablation</title>
          <description>Patients in this group received the cardioneuroablation procedure using the Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter
Cardioneuroablation: Catheter Ablation of Vagal Inputs in Left Atrium
Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter: This is the device that was used to perform the Cardioneuroablation procedure</description>
        </group>
        <group group_id="E2">
          <title>Standard Medical Thearpy</title>
          <description>Patients in this group did not receive the cardioneuroablation and were managed using standard medical therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Angina</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Tremors</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Shingles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. David De Lurgio</name_or_title>
      <organization>Emory University</organization>
      <phone>404-251-1481</phone>
      <email>ddelurg@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

